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Abstract
Introduction: The presence of tumor-infiltrating lymphocytes (TILs) is correlated with good prognosis and outcome
after (immuno)therapy in triple-negative and HER2-positive breast cancer. However, the role of TILs in luminal breast
cancer is less clear. Emerging evidence has now demonstrated that genetic aberrations in malignant cells influence the
immune landscape of tumors. Phosphatidylinositol 3-kinase (PI3K) is the most common altered pathway in ER-positive
breast cancer. It is unknown whether changes in the PI3K pathway result in a different composition of the breast
tumor microenvironment. Here we present the retrospective analysis of a prospective randomized trial in ER-positive
breast cancer on the prognostic and predictive value of specific tumor-associated lymphocytes in the context of PI3K
alterations.
Methods: We included 563 ER-positive tumors from a multicenter trial for stage I to III postmenopausal breast cancer
patients, who were randomized to tamoxifen or no adjuvant therapy. The amount of CD8-, CD4-, and FOXP3-positive
cells was evaluated by immunohistochemistry and quantified by imaging-analysis software. We analyzed the associations
between PIK3CA hotspot mutations, PTEN expression, phosphorylated proteins of the PI3K and MAPK pathway
(p-AKT, p-ERK1/2, p-4EBP1, p-p70S6K), and recurrence-free interval after adjuvant tamoxifen or no adjuvant treatment.
Results: CD8-positive lymphocytes were significantly more abundant in PIK3CA-mutated tumors (OR = 1.65; 95% CI
1.03–2.68). While CD4 and FOXP3 were not significantly associated with prognosis, patients with tumors classified as
CD8-high had increased risk of recurrence (HR = 1.98; 95% CI 1.14–3.41; multivariable model including PIK3CA status,
treatment arm, and other standard clinicopathological variables). Lymphocytes were more often present in tumors
with increased PI3K downstream phosphorylation. This was most pronounced for FOXP3-positive cells.
Conclusion: These exploratory analyses of a prospective trial in luminal breast cancer suggest high CD8 infiltration is
associated with unfavorable outcome and that PI3K pathway alterations might be associated with the composition of
the tumor microenvironment.
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Introduction
The prognosis of early luminal breast cancer patients
has substantially improved after the introduction of
endocrine therapy (tamoxifen and aromatase inhibitors)
[1]. Even so, around 20% of patients still experience re-
currence of disease [2]. Accumulating evidence including
multiple independent studies and meta-analyses have
shown the correlation between tumor-infiltrating lympho-
cytes (TILs) and favorable prognosis in triple-negative
breast cancer (TNBC) and human epidermal growth fac-
tor receptor 2 (HER2)-positive breast cancer [3, 4]. The
prognostic value of TILs in ER-positive/HER2-negative
disease remains relatively unclear, and conflicting results
have been reported [3, 5–13]. There is no solid biological
explanation for this different role of TILs in ER-positive/
HER2-negative breast cancer. Recently, emerging experi-
mental and clinical studies have demonstrated that genetic
aberrations in cancer cells can influence the immune land-
scape of tumors [14–18]. Common drivers of tumorigen-
esis, such as but not limited to p53, Notch, and MYC, can
modulate immune signaling pathways [14–18]. Studying
the relationship between the genetic make-up of luminal
breast carcinomas and the infiltration of specific subsets
of immune cells is crucial for the rational design of clinical
trials evaluating the combination of novel targeted therapy
with immunomodulatory agents.
The phosphatidylinositol 3-kinase (PI3K) pathway is
one of the most altered pathways in luminal breast can-
cer, and large efforts to unravel endocrine resistance
have pointed to aberrant signaling of PI3K, e.g., by
PIK3CA mutations, loss of PTEN, or downstream pro-
tein phosphorylation [19–23]. It led to the development
of treatment strategies like mTOR and PI3K inhibitors
[19, 21, 24, 25]. Adding PI3K inhibitors to standard endo-
crine treatment results in improvement of progression-
free survival (PFS) in patients with metastatic disease with
a PIK3CA-mutated tumor [25]. So far, it is largely un-
known whether PI3K alterations influence the compos-
ition of the tumor microenvironment.
Another treatment strategy that is currently under in-
vestigation in luminal breast cancer includes immune
checkpoint blockade. Although first results suggest that
response rates are modest, durable responses have been
observed in luminal metastatic breast cancer [26]. For
further improvement of immunomodulatory treatments
for luminal breast cancers, evaluating the presence of spe-
cific immune cell subsets as well as a better understanding
of the cancer-immune interactions will be crucial.
T lymphocytes are involved in the cytotoxic adaptive
immunity and play a central role in antitumor immune
responses [27, 28]. Different subpopulations of T lympho-
cytes regulate the balance of immune tolerance and pro-
inflammatory status in tumors [17, 28–30]: CD8-positive
cytotoxic T lymphocytes are involved in interferon gamma
(IFNγ)–dependent mechanisms of antitumor activity
[11, 28, 29]; CD4-positive helper T lymphocytes are im-
portant in activating and regulating the adaptive im-
mune response [28, 30]; in contrast, FOXP3-positive
regulatory T lymphocytes have a crucial role in protecting
tissues from inflammation damage and preventing auto-
immunity [13, 30]. In the tumor microenvironment, regula-
tory T lymphocytes play key roles in inhibiting antitumor
immune responses [29, 31].
A deeper understanding of the prognostic role of these
TIL subsets, their predictive value for endocrine treat-
ment benefit, and the relationship between the TIL sub-
sets and PI3K activity will be useful for future trial
design. It will help to find the optimal patient population
for the evaluation of immunotherapy and/or PI3K inhib-
itors in ER-positive breast cancer. Here we present re-
sults of analyses on the prognostic and predictive value
of specific tumor-associated lymphocytes in the context
of PI3K alterations, using data from a trial in which
breast cancer patients were randomized between adju-
vant tamoxifen and no endocrine treatment.
Materials and methods
Study population and samples
The IKA trial recruited stage I to III postmenopausal
breast cancer patients between 1982 and 1994. Pa-
tients were randomized (2:1) between 1 year of tam-
oxifen (30 mg per day) and no adjuvant therapy. After
1 year, a second randomization was performed between an-
other 2 years of tamoxifen or to stop further treatment.
None of the patients received chemotherapy. The study
data were part of an Oxford systematic review that evalu-
ated the effect of tamoxifen and were previously analyzed
to study and validate biomarkers for tamoxifen resistance
[1, 22, 23, 32–34]. Of 1662 patients included, we were able
to retrieve 739 formalin-fixed paraffin-embedded (FFPE)
tumor blocks. Tissue microarrays (TMAs) were con-
structed using three cores (0.6mm each) per tumor. Of
those tumors, 563 were ER-positive (ERα positivity defined
as ≥ 10% positive tumor cells as determined using immuno-
histochemistry) [22, 23] (Additional file 1: Figure S1). Data
collection of patient characteristics, including the pathology
variables, expression of progesterone receptor (PR), HER2,
and clinical outcome, was described previously [22, 23].
Ki67 staining was evaluated by the percentage of nuclear
positive tumor cells (Additional file 2: Table S1). The
original trial was approved by the central ethics committee
of the Netherlands Cancer Institute (NKI), and informed
consent was obtained from all study participants.
PIK3CA mutation status
DNA isolated from FFPE tumor blocks was genotyped
using Sequenom mass spectrometry–based genotyping
technology to assess the hotspot mutations of the PIK3CA
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gene: in exon 9, 1624G>A (E542K) and 1633G>A (E545K),
and exon 20, 3140A>T (H1047L) and 3140A>G (H1047R),
as described previously [23]. Genotyping for PIK3CA exon
9 mutations was successful in 488 tumor samples, while
exon 20 mutations could be assessed in 491 tumor samples
[23] (Additional file 1: Figure S1).
Evaluation of PI3K pathway activity
Phosphorylation status of proteins from the PI3K path-
way: p-AKT (Thr308 and 473), p-4EBP1 (Ser65), and p-
p70S6K (Thr389); from the MAPK pathway: p-ERK1/2
(Thr202/Tyr204); and PTEN expression were assessed
using immunohistochemistry (IHC) on TMAs. The details
on the IHC analyses and the criteria used for scoring of
these markers were previously reported and are summa-
rized in Additional file 2: Table S1 [22, 23, 33, 34].
Evaluation of the lymphocyte markers
Whole serial sections of 563 ER-positive FFPE tissue
blocks were stained for CD4, CD8, and FOXP3. IHC was
performed using the Ventana Benchmark® Ultra system
(Ventana Medical Systems, Tucson, USA), and details
are provided in Additional file 2: Table S1. The slides
stained for CD8 and CD4 were scanned using the Aperio
Scanner (Leica Biosystems, San Diego, CA, USA) and
automatically evaluated by image-analysis software (Tissue
Image Analysis, version 2.0, Slidepath, Leica Biosystems,
Milton Keynes, UK). The Slidepath software was manually
trained to identify and quantify cells in the image of the
scanned tumor sections according to staining color, size,
and shape of the cells, similar as previously reported [35].
Based on this data, the software calculated the percentage
of positive CD4- and CD8-positive lymphocytes among all
cells of the tumor tissue section. Slides stained for FOXP3
were scanned using the Philips Ultra Fast Scanner 1.6 RA.
FOXP3 nuclear positivity of lymphocytes in intratumoral
and in surrounding stroma tissue was automated measured
by AxioVision 4.6 (Carl Zeiss Vision, Jena, Germany),
as previously described [8]: four fields per slide (in aver-
age 1.5 mm2 per field) were used to count the number
of FOXP3-positive cells per mm2.
Since the distribution of the expression values of these
markers showed lognormal properties, we took the loga-
rithm of these values and centered the resulting distribu-
tions in zero by subtracting the logarithmic median of
each marker. Two certified pathologists (HH and KVdV)
and a molecular biologist (Iz) scored the percentage of
CD4-, CD8-, and FOXP3-positive lymphocytes in a se-
lected number of cases (HH: n = 33, KVdV: n = 30, and
Iz: n = 100). Samples quantified as zero in the automated
and normalized expression correspond, approximately, to
the following pathologists’ scores: 5% CD4-, 15% CD8-,
and 1% FOXP3-positive cells, respectively (Additional file 1:
Figure S2). From the 563 ER-positive breast cancer
patients included in the trial, 161 to 185 tumor samples
had insufficient tumor material to evaluate the expression
of these markers. We could quantify CD4, CD8, and
FOXP3 expression in 396, 402, and 378 tumor samples,
respectively (Additional file 1: Figure S1).
Statistical analyses
Associations were evaluated by the chi-square test or by
Fisher exact test if one of the expected counts were less
than 5. Comparison between pathologists’ and the ex-
pression of lymphocyte markers obtained by automated
fashion was calculated by Spearman’s rank correlation
test and by the intraclass correlation coefficient (ICC;
assuming two-way random single measures) [36]. Com-
parisons of means between two or more groups were ex-
amined by Student’s t test or ANOVA, respectively.
Odds ratios (OR) with their respective 95% confidence
intervals (95% CI) were calculated using binomial logis-
tic multivariable regression models to measure the asso-
ciation between lymphocyte markers and PIK3CA
mutation status. Associations between tumor variables
and lymphocytes or (phospho-) protein levels were cal-
culated by linear regression models and quantified in re-
gression coefficients (r) and their 95% CI.
Survival time was calculated from the date of
randomization. End of follow-up was defined as the date
of an event, lost to follow-up, or 10 years time at risk
(censoring), whatever came first. The recurrence-free
interval (RFI) was defined as the time from the date of
first randomization until the occurrence of a local, re-
gional, or distant recurrence, or breast cancer-specific
death [22]. Breast cancer-specific interval (BCSI) was de-
fined as death caused by breast cancer progression or a
breast cancer treatment-related event. Secondary pri-
mary breast tumor was not considered an event, and
these patients were censored at the date of this occur-
rence [22].
Hazard ratios (HRs) and 95% CI were estimated using
Cox regression models. Of note, after 1989, two interim
analyses showed a significant improvement in RFI in
lymph node (LN)-positive patients. After this year, LN-
positive patients in this trial skipped the first randomization
and all received 1 year of tamoxifen [32]. Therefore, multi-
variable Cox regression models were stratified by LN status.
Regression analysis included the following variables in the
(logistic, linear, and Cox) multivariable models: morphology
type (ductal, lobular, or others), tumor grade (1, 2, or 3),
tumor size (≤ 2 cm or > 2 cm), PR (negative or positive),
HER2 (negative or positive), and PIK3CA mutation status
(wild-type or mutated). Cox regression models also in-
cluded age at diagnosis (as continuous value) and tamoxifen
arm (treated or control). Splined curves of the Cox regres-
sion terms against the expression of lymphocyte markers
were used to check for non-linear associations (degree of
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freedom= 3) [37]. Cut-off estimations for the lymphocyte
markers (low or high) were based on the best sensitivity
and specificity measures for RFI prediction [38]. We used a
freely available web application to calculate the threshold
(R package: Optimal.cutpoints). The method (MaxKappa)
makes full use of the clinical and molecular information to
assess the prediction value over chance [39, 40].
Unsupervised hierarchical clustering and Euclidean
dissimilarity was conducted on phosphorylation levels
and protein expression values, centered and proportion-
ally scaled. Results of regression models were obtained
using patients with complete data only.
All p values reported are from two-sided tests, and the
threshold for significance was set at p = 0.05. No correc-
tion for multiple testing was applied. All statistical ana-
lyses were performed using RStudio version 3.2.3 (RStudio
Team, 2015).
Results
CD4, CD8, and FOXP3 expression and standard
clinicopathological features
Cells positively stained for CD4, CD8, and FOXP3 were
mainly found in the stromal areas (Additional file 1:
Figure S3A-F). The average scores from two patholo-
gists were compared with the expression values obtained
by image-analysis software (rCD4 = 0.752, rCD8 = 0.796, and
rFOXP3 = 0.836; Additional file 1: Figure S3G-I). The pres-
ence of CD4-, CD8-, and FOXP3-positive cells was strongly
correlated (rCD8/FOXP3 = 0.576, rFOXP3/CD4 = 0.503, and
rCD4/CD8 = 0.652; Fig. 1a–c).
Figure 1d–f shows the correlation between CD4-, CD8-,
and FOXP3-positive cells and clinicopathological character-
istics as calculated by multivariable linear regression. More
CD8-, CD4-, and FOXP3-positive cells were detected in
high-grade tumors (grade 3) (all p < 0.001; univariable ana-
lyses in Additional file 1: Figure S4A-C). In line with these
associations, tumors with high Ki67 scores were associated
with higher levels of CD4, CD8, and FOXP3 (p < 0.001;
Additional file 1: Figure S4D-F). HER2-positive tumors
showed higher CD8 expression compared with HER2-
negative tumors (rCD8 = 0.36, p = 0.040; Fig. 1e). FOXP3
expression was significantly lower in large tumors (> 2 cm;
rFOXP3 = − 0.38, p = 0.018) and in lobular carcinomas
(rFOXP3 = − 0.59, p = 0.015; Fig. 1f ), compared with
ductal carcinomas (p < 0.001; Additional file 1: Figure S4I).
CD4, CD8, and FOXP3 expression and PIK3CA mutations
PIK3CA mutations in exon 9 or exon 20 were found in
159 (32.7%) of the 486 tumors genotyped [23]. In total,
296 patients had complete information for PIK3CA
mutation and the three immune markers. The tumor
microenvironment of PIK3CA-mutated tumors was infil-
trated with relatively more CD8-positive cells compared to
wild-type tumors (p = 0.038, Fig. 2a, b). Linear multivariable
regression models showed a relatively weak but statistically
significant correlation between PIK3CA mutation status
and higher CD4 and CD8 levels (rCD4 = 0.25, p = 0.030 and
rCD8 = 0.27, p = 0.005; Fig. 1d, e).
Two specific PIK3CA mutations were associated with
CD8 infiltration: tumors harboring 1633G>A mutations
in exon 9 or 3140A>G in exon 20 showed slightly higher
CD8 expression compared with the wild-type tumors
(p1633G>A = 0.0473; Additional file 1: Figure S5B and
p3140A>G = 0.0322; Additional file 1: Figure S5E).
As previously reported by our group and others [23, 41],
low-grade tumors (grade 1 or 2) are likely to have more
PIK3CA mutations (ORgrade 3vs1 = 0.18; 95% CI 0.08–0.38;
Fig. 2a). Within these low-grade tumors, the correlation
between CD8 levels and PIK3CA mutation status was
more pronounced (p = 0.001; Fig. 2c).
CD4, CD8, and FOXP3 expression and breast cancer outcome
Continuous CD4, CD8, and FOXP3 expression levels
were not significantly associated with RFI in the Cox lin-
ear regression models (data not shown). To illustrate
this, we plotted the partial residuals of the (univariate
and multivariable) Cox regression models for each
lymphocyte marker (Additional file 1: Figure S6A-F).
However, it is known that continuous variables can be
associated with the hazard in a non-linear way [42]. The
spline function of the fitted partial residual values of the
Cox regression models for each lymphocyte marker
indeed showed a non-linear shape (Additional file 1:
Figure S6G-I). Since there is no established cut-off for
CD4, CD8, and FOXP3 available yet, these spline plots
were used to identify the best cut-off points in the scale of
the expression of the lymphocyte markers according to the
largest differences in the recurrence rates (Additional file 1:
Figure S6J-L). The splined curves highlighted the increase
of partial residual values of patients classified as high CD4,
CD8, and FOXP3 (Fig. 3a–c). The Kaplan-Meier curves
illustrate that patients with tumors harboring high levels of
CD8 (29 of the total of 410 tumors) have a worse RFI com-
pared to patients with low CD8 tumors (log-rank test; p <
0.001; Fig. 3e). After multivariable adjustment for PIK3CA
mutation and other pathological variables, this association
remained significant: HRhigh-CD8 = 1.98; 95% CI 1.14–3.41
(Fig. 3e and Additional file 1: Figure S7A). Associations
between RFI and CD4 and FOXP3 expression were not sta-
tistically significant after multivariable analysis (Fig. 3d, f,
and Additional file 1: Figure S7A). After exclusion of the
patients with HER2-positive disease, we still observe a sig-
nificantly worse RFI in patients with high CD8 expression
in the tumor microenvironment (HRhigh-CD8 = 1.87; 95% CI
1.07–3.28, p < 0.0001).
While ER-positive breast tumors with low grade are
considered to have a relative good prognosis in breast
cancer [1], within these low-grade tumors, we observed
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that high levels of CD4 or CD8 were associated with
poor outcome (log-rank test; p < 0.0001; Fig. 3g, h). The
effect remained significant after adjustment for known
prognostic factors (Fig. 3g, h, and Additional file 1:
Figure S7B). Similar associations were observed when
using BCSI as endpoint (Additional file 1: Figure S7C
and D).
CD8 expression and breast cancer outcome according to
tamoxifen treatment
The proportion of patients identified with CD8-high tu-
mors corresponded to only 7.2% of total tumors quanti-
fied (n = 410; Fig. 4a). We evaluated the prognostic value
of CD8 status within each arm of the trial: not-treated
and treated with tamoxifen (1 or 3 years after surgery).
High CD8 levels were associated with poor RFI regard-
less of tamoxifen treatment (log-rank test; p < 0.001 and
p = 0.040, respectively; Fig. 4b, c). However, univariate
HR remained significant only for the control arms. The
p value for interaction between CD8 status and tamoxi-
fen treatment in a full model for RFI was 0.082. Since
patients with HER2-positive tumors did not receive tras-
tuzumab, we applied the same analysis in the HER2-
negative patients only. The proportion of CD8-high
tumors and RFI associations observed in this subgroup
(n = 355) were similar to whole ER-positive group.
Fig. 1 Correlations between the expression of lymphocyte markers and pathological features. a–c Correlation plots of the expression of the three
lymphocyte markers. Each graph includes a regression line and the Spearman coefficient of the correlation between the two markers; the
expression of the third marker is indicated by the color degree of the dots: CD8 in blue, CD4 in green, and FOXP3 in red. d–f The plots
graphically present the magnitude of the association between each pathological feature and the expression of lymphocyte markers: CD4 (d), CD8
(e), and FOXP3 (f). Coefficients with 95% confidence intervals were estimated using multivariable linear regression models (based on cases with
complete information). Abbreviations: pN0 lymph node negative, pN1+ lymph node positive, PR progesterone receptor, HER2 human epidermal
growth factor receptor 2, PIK3CA mutations in exon 9 and/or exon 20
Sobral-Leite et al. Breast Cancer Research           (2019) 21:90 Page 5 of 12
Of note, after the first interim analyses of the IKA
trial, it was decided that LN-positive patients would skip
the first randomization. After this point, all LN-positive
patients received 1 year of tamoxifen [32]. Thus, we
calculated the effect of adjuvant tamoxifen during 1 or
3 years according to CD8 status, by applying regression
analysis grouped by LN status, but it did not change
our conclusions (Additional file 1: Figures S8, S9, and
Additional file 2: Table S2).
CD4, CD8, and FOXP3 expression and the activation of
PI3K pathway in breast tumors
Unsupervised hierarchical clustering revealed that tu-
mors with increased levels of CD4, CD8, and FOXP3
also had higher phosphorylation levels of proteins from
the PI3K pathway (right side of dendrogram and heat
map, Fig. 5a).
In order to statistically evaluate this link between the
specific phosphorylation of the PI3K pathway and the
presence of lymphocytes, we performed multivariable
linear regression models including pathological variables
and PIK3CA mutation status (Additional file 2: Tables
S3A-F). In general, we found a weak positive correlation
between the phosphorylation levels of PI3K pathway and
lymphocyte infiltration. More specifically, p-AKT(Ser473),
p-ERK1/2, and p-p70S6K were statistically significant as-
sociated with high CD4 (p = 0.045, 0.003, and 0.007, re-
spectively; Fig. 5b). A similar pattern was observed for the
associations with CD8, in which p-AKT(Thr308), p-
AKT(Ser473), and p-p70S6K reached statistical signifi-
cance (p = 0.030, 0.009, and 0.004, respectively; Fig. 5c).
Phosphorylation levels of the PI3K markers and PTEN ex-
pression were all positively and significantly correlated
with FOXP3 expression (almost all p < 0.001, Fig. 5d and
Additional file 2: Tables S3A-F). Exclusion of the HER2-
positive cases did not substantially change the results
(data not shown).
Taking together, ER-positive breast tumors with high
levels of TILs show more activation of downstream pro-
teins of the PI3K pathway.
Discussion
We performed post hoc analysis of TIL composition and
PI3K alterations in a trial that compared the outcome of
ER-positive breast cancer patients, randomized between
adjuvant tamoxifen (1–3 years), and patients who re-
ceived no adjuvant treatment. For CD4 and FOXP3
expression, we did not find an association with outcome.
In contrast, our analyses in the total cohort of ER-positive
tumors as well as in the ER-positive/HER2-negative
A B C
Fig. 2 Expression of the lymphocyte markers and PIK3CA mutation status. a Forest plot graphically represents the magnitude of the association
between each pathological feature and PIK3CA mutation status, calculated by multivariable logistic regression model (as complete case analysis).
b Distribution of CD8 expression according to PIK3CA mutation status in all tumors and c within grade 1 or 2 tumors. Statistical differences
between the expression means among the two categories were calculated by t test: p(t). Abbreviation: pN0 lymph node negative, pN1+ lymph
node positive, PR progesterone receptor
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subgroup suggest that patients with ER-positive tumors
with very high infiltration of CD8-positive lymphocytes
are more likely to have recurrence of disease. This associ-
ation is in the opposite direction of the established link
observed between high TILs and improved prognosis in
TN and HER2-positive breast cancer [4, 5, 7, 11]. But in
the largest observational study so far on CD8, Ali et al. de-
scribed a relatively poor outcome for CD8-high tumors
Fig. 3 Association between CD4, CD8, and FOXP3 expression and relapse-free interval (RFI). Partial residuals of the multivariable Cox regression
models were plotted against the CD4 (a), CD8 (b), and FOXP3 (c) expression. Smoothed lines were drawn based on the spline function of the
fitted partial residual values of the Cox regression (RFI; 5 years follow-up) and their standard error range. Vertical gray dashed lines show the
threshold used to classify status low and high for each lymphocyte marker, estimated by sensitivity/specificity measurements of differences in RFI.
Kaplan-Meier curves and adjusted hazard ratios (HRs) of CD4, CD8, and FOXP3 status were calculated in the whole group (d, e, and f, respectively)
and among patients with low-grade tumors (g, h, and i, respectively). Statistical differences between the groups were calculated by the log-rank
test (p). Multivariable models were stratified by lymph node status and included the following variables: CD4, CD8, and FOXP3 status; morphology
type; tumor grade; tamoxifen arm; tumor size; age at diagnosis; PR; HER2; and PIK3CA mutation status. Abbreviation: HR hazard ratio, CI
confidence interval, ER estrogen receptor, RFI relapse-free interval
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within the ER-positive/HER2-negative subgroup [5]. In
addition, our exploratory data is also in line with a recent
meta-analysis showing that an increase in TILs is associ-
ated with shorter overall survival in luminal–HER2-nega-
tive tumors (HR = 1.10; 95% CI 1.02–1.19, p = 0.011) [7].
Even though we determined CD8-high threshold using
the survival data of this series, which resulted in over-
fitting, these large studies support the link we found
between high CD8 expression and poor survival in
luminal breast cancer. A clear explanation for this op-
posite effect of TIL in ER-positive disease versus pat-
terns seen in TN or HER2-positive breast cancer is still
lacking. We checked if tumors with high levels of CD8-
positive lymphocytes would also be the ones expressing
a lower percentage of ER positivity but no association
was found (Additional file 1: Figure S10).
FOXP3 expression did not show significant prognostic
value, similar to results from Ali et al. [5], Mahmoud et
al. [12], and Baker et al. [6]. However, other studies have
reported statistically significant associations between
FOXP3+ and poor survival in breast cancer [9, 13]. Al-
though FOXP3 status alone was not predictive for recur-
rence risk in our data, its expression was highly correlated
with CD4 and CD8 expression. However, scoring of
FOXP3-positive lymphocytes remains challenging for pa-
thologists since these cells are often scattered in the
Fig. 4 Association between CD8 status and tamoxifen benefit. The boxplots show the distribution of CD8 scores among all ER-positive tumors
(a). The proportion of patients with the tumors classified as high-CD8 based on the cut-off defined in Fig. 3 are plotted in green. Kaplan-Meier
curves and adjusted hazard ratios (HRs) of CD8 status were calculated in patients who did not receive adjuvant tamoxifen (b) and who received
adjuvant tamoxifen for 1 or 3 years (c). The same analysis was applied within ER-positive/HER2-negative patients (d, e, and f). Statistical differences
in survival were calculated by the log-rank test (p). Multivariable models were stratified by lymph node status and included CD4, CD8, and FOXP3
status; morphology type; tumor grade; tumor size; age at diagnosis; PR; HER2 (when applicable); and PIK3CA mutation status. Abbreviation: HR
hazard ratio, CI confidence interval, ER estrogen receptor, RFS relapse-free survival
Sobral-Leite et al. Breast Cancer Research           (2019) 21:90 Page 8 of 12
stroma. Moreover, the dynamic range of FOXP3 expres-
sion in the breast tumor microenvironment is limited
(0–15%; illustrated in Additional file 1: Figure S3I).
Of note, we also analyzed the CD8/FOXP3 as well as
the CD4/FOXP3 ratio and no significant association
with survival was observed (data not shown). Further
validation of the prognostic value of TIL subsets in
luminal breast cancer is required.
The activation of the PI3K pathway plays a central role
in cancer growth and tamoxifen resistance [19–21, 23].
Preclinical data suggested that deregulation of the PI3K
pathway could contribute to immune escape [43]. On
the other hand, detailed information on the cross-talk
between the immune infiltrate and cancer cells harboring
an aberration in the PI3K pathway in vivo is scarce. Using
a large set of breast cancer patients who received adjuvant
chemotherapy, Kotoula et al. did not show a clear associ-
ation between TILs and PIK3CA mutations [44]. In order
to investigate the association between the actual activation
of the PI3K pathway and immune infiltration, we assessed
phosphorylation levels of proteins downstream of PI3K in
parallel with TIL subsets defined by CD4, CD8, and
FOXP3 [22, 23]. Our analyses of TIL subsets in the con-
text of PI3K alterations revealed that tumors with a
PIK3CA mutation tend to have more CD8 cells and tu-
mors enriched for FOXP3-positive cells show downstream
activation of the PI3K pathway. Previously, we have shown
the lack of clear association between mutations in PIK3CA
Fig. 5 Lymphocytic infiltration and PI3K pathway activation in breast tumors. a Heat map represents unsupervised hierarchical clustering of 215
breast carcinomas (columns) based on the expression of lymphocyte markers and the activation of PI3K pathway on tumor cells (rows). Information on
percentage of ER positivity (from 10 to 100%) and tumor grade (1, 2, or 3) is indicated by gray scale: low as lighter gray and high as darker gray. Boxes
of PIK3CA mutation status are filled with gray (wild-type), black (mutated), or white (unknown). CD4, CD8, and FOXP3 status was filled with color (high)
or gray (low). The forest plots represent multivariable linear regression models. Each plot merges 6 multivariable models (described in Additional file 2:
Tables S2A-F) calculating the association between the (phospho-) levels of PI3K downstream proteins and CD4 (b), CD8 (c), or FOXP3 (d) expression.
Measurements of these associations are represented by the coefficients plotted on the x axes. The size of each dot is proportional to the number of
samples used for each multivariable complete case analysis, and bars represent the standard deviation
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and activation of downstream proteins in the PI3K/AKT/
mTOR pathway [23]. PIK3CA exon 20 mutations are
associated with higher p-ERK1/2 levels that belong to the
MAP kinases pathway, and tumors with a PIK3CA exon
9 mutation are associated with higher p-AKT and p-
ERK1/2, but not with p-p70S6K [23]. Our current study
illustrates that cancer-immune interactions might differ
depending on specific alterations in PI3K pathway.
Interestingly, our data are in line with Crane et al., who
demonstrated using in vitro models that breast carcin-
oma cells with activated PI3K pathway, once exposed to
activated T cells, adopt an immune-resistant phenotype
by increasing the percentage of FOXP3-expressing lym-
phocytes [43]. More functional studies are needed for a
better understanding of the specific interactions between
the multifunctional PI3K pathway and the various compo-
nents of the pro- and anticancer immune response.
We also evaluated the benefit of adjuvant tamoxifen
according to the CD8 status of their tumor. Within pa-
tients classified as CD8-low, no significant RFI improve-
ment was detected when patients were treated with
adjuvant tamoxifen, compared with the control group.
Similarly, Blok et al. also observed a limited benefit of
adjuvant tamoxifen relative to exemestane within pa-
tients with a low number of CD8 TILs [45]. More stud-
ies exploring the predictive value of tumor-immune
profiles are needed.
Limitations of our study include the relatively small
sample size and lack of correction for multiple testing.
Furthermore, the patients included in our study did not
receive endocrine treatment during 5–10 years or aro-
matase inhibitors, according to the current guidelines.
Therefore, it remains to be determined whether tumor-
associated immune cells are associated with long-term
benefit of endocrine treatment. Although we evaluated
the PIK3CA-immune interaction in a dataset of a pro-
spective trial, this analysis was not preplanned and should
therefore be considered exploratory.
Insufficient data is available on combination treatment
with immunotherapy plus PI3K inhibition in luminal breast
cancer. Recently, the randomized, phase 3 SOLAR-1 trial
showed that the treatment with alpelisib, a PI3Kα-specific
inhibitor, in combination with fulvestrant prolonged
progression-free survival among patients with PIK3CA-
mutated, ER-positive/HER2-negative advanced breast
cancer [46]. Given that patients with a PIK3CA muta-
tion in the tumor might have more benefit from PI3K
inhibition [24, 25, 47], and, according to our data, could
have more tumor-associated CD8, a combination treat-
ment with immune checkpoint blockade plus PI3K in-
hibition deserves exploration in a clinical trial. Notably,
combined PI3K and CDK4/6 inhibition, along with im-
mune checkpoint inhibition induced durable regres-
sions of TN breast cancer tumors in vivo [48]. Based
on our observation that PI3K activation is associated
with higher levels of regulatory T cells, the develop-
ment of PI3K inhibitors in combination with immuno-
modulatory agents that are able to deplete regulatory T
cells might be of interest for luminal breast cancer [43].
Conclusion
In this dataset of ER-positive breast cancer, tumor infiltra-
tion of CD8-positive lymphocytes was associated with
PIK3CA mutations and worse clinical outcome. These asso-
ciations were more pronounced among patients with grade
1 or 2 tumors. Furthermore, activation of the PI3K pathway,
measured using phosphorylated downstream proteins, in
breast tumor cells was positively correlated with tumor-
infiltrating FOXP3-positive lymphocytes. Further validation
of these cancer-immune interactions in ER-positive breast
tumors might provide useful information for further devel-
opment of immunomodulatory combination treatments for
ER-positive breast cancers with highTILs.
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